Oric Pharmaceuticals, Inc. (ORIC) intrinsic value & 10-year financials
Oric Pharmaceuticals, Inc. (ORIC) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $12.35
- Market cap
- $1.1B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -47.0%
- Free cash flow (FY2025)
- -$111.7M
ORIC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$129.5M | -$1.47 | -$111.7M | — | -53.7% |
| FY2024 | — | -$127.8M | -$1.83 | -$113.8M | — | -71.8% |
| FY2023 | — | -$100.7M | -$1.96 | -$86.5M | — | -59.4% |
| FY2022 | — | -$89.1M | -$2.25 | -$77.2M | — | -78.8% |
| FY2021 | — | -$78.7M | -$2.07 | -$60.5M | — | -116.0% |
| FY2020 | — | -$73.7M | — | -$45.9M | — | -74.3% |
| FY2019 | — | -$26.9M | — | -$24.3M | — | 37.0% |
| FY2018 | — | -$21.4M | — | -$21.2M | — | 41.4% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Oric Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Oric Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -47.0% ROIC.
Oric Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Oric Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.